FDA curbs use of antibody drugs sidelined by omicron
By MATTHEW PERRONE AP Health Writer WASHINGTON (AP) — U.S. health officials say COVID-19 antibody drugs from Regeneron and Eli Lilly should no longer be used because they are unlikely to work against the omicron variant. The Food and Drug Administration said Monday it is revoking emergency authorization for both drugs. If they prove effective
Continue Reading